Vimarsana
Biggest News Aggregation in the World

Preclinical Model News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preclinical Model. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preclinical Model Today - Breaking & Trending Today

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting - Vimarsana News

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...

Singapore Scientists Discover That a Special Supplement Could Treat Acute Kidney Injury - Vimarsana News

Singapore Scientists Discover That a Special Supplement Could Treat Acute Kidney Injury

Scientists from Singapore have discovered a possible dietary supplement that could improve recovery after acute kidney injury (AKI). The finding, published in the Journal of Lipid Research, is the result of a long-running research program at Duke-NUS Medical School investigating how cells take up a

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO - Vimarsana News

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting - Vimarsana News

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses ... - Vimarsana News

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses ...

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in